NCCN Quick Guide™ | Chronic Myeloid Leukemia
2 of 2 NCCN QUICK GUIDE tm Chronic Myeloid Leukemia, 2018 PAT-N-1019-1017 What are the treament options for accelerated CML? Clinical trial. 36 TKI (imatinib, dasatinib, nilotinib, bosutinib, ponatinib). Omacetaxine. For long-term cancer control, an HCT is needed. What are the treatment options for blast CML? Treatment options are based on the main cell type—lymphoid or myeloid. 37 A clinical trial is an option for either type. TKI (imatinib, dasatinib, nilotinib, bosutinib, ponatinib) and chemotherapy. The type of chemotherapy depends on main cell type. TKI with a steroid for lymphoid cell type. TKI alone for myeloid cell type. For long-term control, an HCT is needed. What are the options after HCT? If treatment worked, think about taking a TKI for a year 38 If treatment did not work, options include TKI, TKI + donor lymphocyte infusion, omacetaxine, and a clinical trial. What are some tips for deciding treatment? Ask your doctors many questions. Also, you can get a second opinion, attend support groups, and compare pros and cons. 41 NCCN Guidelines for Patients ® Page Number Ü NCCN.org/patients - for Patients | NCCN.org - for Clinicians DONATE NOW NCCNFoundation.org/Donate The NCCN QUICK GUIDE tm series and NCCN Guidelines for Patients ® are supported by charitable donations made to the NCCN Foundation ® . For more details and the full library of patient and caregiver resources, visit NCCN.org/patients.
Made with FlippingBook